研究领域
[1]海洋生物多肽分子的发现与生物活性研究;
[2]毒素多肽的合成、化学修饰和结构改造研究;
[3]毒素多肽与离子通道等受体作用的分子机制研究
近期论文
查看导师新发文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
[1] Ren J, Zhu X, Xu P, Li R, Fu Y, Dong S, Zhangsun D,Wu Y, Luo S. d-Amino Acid Substitution of alpha-Conotoxin RgIA Identifies its Critical Residues and Improves the Enzymatic Stability. Marine drugs 2019;17(3).
[2] Ren J, Li R, Ning J, Zhu X, Zhangsun D,Wu Y*, Luo S. Effect of Methionine Oxidation and Substitution of alpha-Conotoxin TxID on alpha3beta4 Nicotinic Acetylcholine Receptor. Marine drugs 2018;16(6).
[3] Ning J, Li R, Ren J, Zhangsun D, Zhu X,Wu Y*, Luo S. Alanine-Scanning Mutagenesis of alpha-Conotoxin GI Reveals the Residues Crucial for Activity at the Muscle Acetylcholine Receptor. Marine drugs 2018;16(12).
[4]Wu Y, Zhangsun D, Zhu X, Kaas Q, Zhangsun M, Harvey PJ, Craik DJ, McIntosh JM, Luo S. alpha-Conotoxin [S9A]TxID Potently Discriminates between alpha3beta4 and alpha6/alpha3beta4 Nicotinic Acetylcholine Receptors. Journal of medicinal chemistry 2017;60(13):5826-5833.
[5]Wu Y, Wu X, Yu J, Zhu X, Zhangsun D, Luo S. Influence of disulfide connectivity on structure and bioactivity of alpha-conotoxin TxIA. Molecules 2014;19(1):966-979.
[6] Fu Y, Li C, Dong S,Wu Y, Zhangsun D, Luo S. Discovery Methodology of Novel Conotoxins from Conus Species. Marine drugs 2018;16(11).
[7] Li X, Hu Y,Wu Y, Huang Y, Yu S, Ding Q, Zhangsun D, Luo S. Anti-hypersensitive effect of intramuscular administration of alphaO-conotoxin GeXIVA[1,2] and GeXIVA[1,4] in rats of neuropathic pain. Progress in neuro-psychopharmacology & biological psychiatry 2016;66:112-119.
[8] Lin B, Xu M, Zhu X,Wu Y,Liu X, Zhangsun D, Hu Y, Xiang S-H, Kasheverov IE, Tsetlin VI, Wang X, Luo S. From crystal structure of α-conotoxin GIC in complex with Ac-AChBP to molecular determinants of its high selectivity for α3β2 nAChR. Scientific reports 2016;6:22349.
[9] Luo S, Zhangsun D, Harvey PJ, Kaas Q,Wu Y,Zhu X, Hu Y, Li X, Tsetlin VI, Christensen S, Romero HK, McIntyre M, Dowell C, Baxter JC, Elmslie KS, Craik DJ, McIntosh JM. Cloning, synthesis, and characterization of alphaO-conotoxin GeXIVA, a potent alpha9alpha10 nicotinic acetylcholine receptor antagonist. Proceedings of the National Academy of Sciences of the United States of America 2015;112(30):E4026-4035.
[10] Luo S, Zhangsun D, Schroeder CI, Zhu X, Hu Y,Wu Y,Weltzin MM, Eberhard S, Kaas Q, Craik DJ, McIntosh JM, Whiteaker P. A novel alpha4/7-conotoxin LvIA from Conus lividus that selectively blocks alpha3beta2 vs. alpha6/alpha3beta2beta3 nicotinic acetylcholine receptors. FASEB journal 2014;28(4):1842-1853.
[11] Yu S, Wu Y, Xu P, Wang S, Zhangsun D, Luo S. Effects of serum, enzyme, thiol, and forced degradation on the stabilities of alphaO-Conotoxin GeXIVA[1,2] and GeXIVA [1,4]. Chemical biology & drug design 2018;91(5):1030-1041.
[12] Zhangsun D, Zhu X, Kaas Q,Wu Y, Craik DJ, McIntosh JM, Luo S. alphaO-Conotoxin GeXIVA disulfide bond isomers exhibit differential sensitivity for various nicotinic acetylcholine receptors but retain potency and selectivity for the human alpha9alpha10 subtype. Neuropharmacology 2017;127:243-252.
[13] Zhangsun D, Zhu X,Wu Y, Hu Y, Kaas Q, Craik DJ, McIntosh JM, Luo S. Key residues in the nicotinic acetylcholine receptor beta2 subunit contribute to alpha-conotoxin LvIA binding. The Journal of biological chemistry 2015;290(15):9855-9862.
[14] Sulan Luo;Xiaopeng Zhu;Yong Wu;DongtingZhangsun. Conotoxins and Drug Discovery with Special Reference to Hainan Species, 2017, Springer